Addex CEO Reports 8.9% Stake
Addex Therapeutics Ltd. (NASDAQ: ADXN) has received an amended Schedule 13D filing from Chief Executive Officer and board member Timothy Mark Dyer, updating his beneficial ownership in the company. The filing was submitted on August 27, 2026, following an increase in Addex’s outstanding share count. Dyer reported beneficial ownership of 19,095,510 ordinary shares, representing approximately…









